Orange County NC Website
Browse       Search
8 <br /> The limited immunity provided in this subsection shall apply only if the person claiming <br /> immunity provides written verification that a needle, syringe, or other injection supplies were <br /> obtained from a needle and hypodermic syringe exchange program established pursuant to this <br /> section. In addition to any other applicable immunity or limitation on civil liability, a law <br /> enforcement officer who, acting on good faith, arrests or charges a person who is thereafter <br /> determined to be entitled to immunity from prosecution under this section shall not be subject <br /> to civil liability for the arrest or filing of charges. <br /> fcll Prior to commencing operations of a program established pursuant to this section, <br /> the governmental or nongovernmental organization shall report to the North Carolina <br /> Department of Health and Human Services, Division of Public Health, all of the following <br /> information: <br /> al The legal name of the organization or agency operating the program. <br /> al The areas and populations to be served by the program. <br /> al The methods by which the program will meet the requirements of subsection <br /> (b) of this section. <br /> fel Not later than one year after commencing operations of a program established <br /> pursuant to this section, and every 12 months thereafter, each organization operating such a <br /> program shall report the following information to the North Carolina Department of Health and <br /> Human Services, Division of Public Health: <br /> al The number of individuals served by the program. <br /> al The number of needles, hypodermic syringes, and needle injection supplies <br /> dispensed by the program and returned to the program. <br /> al The number of naloxone kits distributed by the program. <br /> The number and type of treatment referrals provided to individuals served by <br /> the program, including a separate report of the number of individuals <br /> referred to programs that provide access to naloxone hydrochloride that is <br /> approved by the federal Food and Drug Administration for the treatment of a <br /> drug overdose." <br /> SECTION 5. Sections 1, 2, and 3 of this act become effective October 1, 2016, and <br /> apply to all requests made on or after that date for the disclosure or release of a recording. The <br /> remainder of this act is effective when it becomes law. <br /> In the General Assembly read three times and ratified this the 30th day of June, <br /> 2016. <br /> s/ Daniel J. Forest <br /> President of the Senate <br /> s/ Tim Moore <br /> Speaker of the House of Representatives <br /> s/ Pat McCrory <br /> Governor <br /> Approved 2:51 p.m. this 11th day of July, 2016 <br /> Page 6 Session Law 2016-88 House Bill 972 <br />